Analyst Research Report Snapshot

Title:

BASILEA - CATALYSTS IN VIEW

Price:

$10.00

Provider:

Edison Investment Research

Date:

12 Jan 2012

Pages:

2

Type:

AcrobatPDF

Companies referenced:

BSLN.S

Available for Immediate Download
Summary:

The completion of the pneumonia data audit and confirmation of the timeline for Basilea’s European data filing of ceftobiprole brings the company a step closer to achieving a licensing deal for the drug. Global sales of other broad spectrum antibiotics are in a high growth phase. The investment case is strongly dependent on securing US and/or European partnerships for ceftobiprole. Meanwhile the US future for the drug hinges on a decision from the FDA on the need for further trials.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.